ライフサイエンスコーパス: monotherapy

1 mbination with ranibizumab 0.5 mg (anti-VEGF monotherapy).

2 an monotherapy and 151 patients to tadalafil monotherapy).

3 eatment compared with switching to bupropion monotherapy.

4 t that nearly 20% are hypersensitive to CHKi monotherapy.

5 substantially improving survival compared to monotherapy.

6 re key metabolic pathways relative to either monotherapy.

7 ens and tumor Ags that is superior to either monotherapy.

8 tive administration schedule for gemcitabine monotherapy.

9 7; 95% CI, 1.10-1.70) compared with estrogen monotherapy.

10 3 drugs improve VA similarly over 1 year of monotherapy.

11 ed with combined therapy versus benznidazole monotherapy.

12 human xenograft models compared with either monotherapy.

13 the protective effect of transient BAFFR-Fc monotherapy.

14 in several lymphomas, but is not curative as monotherapy.

15 for those with rhinitis poorly controlled on monotherapy.

16 ely 30% of heavily pretreated MM patients as monotherapy.

17 cant reduction in recurrent VTE with aspirin monotherapy.

18 s were compared to 37 eyes under bevacizumab monotherapy.

19 trols) and was comparable with ciprofloxacin monotherapy.

20 have superior efficacy compared to inhibitor monotherapy.

21 cycle arrest, and delays resistance to EGFR monotherapy.

22 made for or against using cesium-131 or HDR monotherapy.

23 ater antitumor activity than each respective monotherapy.

24 ), LDR brachytherapy alone may be offered as monotherapy.

25 ab doses; 64 (42%) remained on pembrolizumab monotherapy.

26 higher rate of irAEs than either approach as monotherapy.

27 2%) in 90-day mortality favoring beta-lactam monotherapy.

28 irudin than among those who received heparin monotherapy.

29 on for >2 years on anti-PD-1 (pembrolizumab) monotherapy.

30 therapy is more efficacious than ACEI or ARB monotherapy.

31 gic and immunomodulator compared to biologic monotherapy.

32 in the serum and stools throughout ribavirin monotherapy.

33 ance mechanisms that limit efficacy of PARPi monotherapy.

34 h relapsed/refractory MM received venetoclax monotherapy.

35 d combination therapy and 208 (61%) received monotherapy.

36 er risk of first-time MI and stroke than ASA monotherapy.

37 pond to either EGFR antagonist or DR agonist monotherapies.

38 ht improve overall survival as compared with monotherapies.

39 PGA, any non-PGA, latanoprost, or travoprost monotherapies.

40 ts (>/=21 days) with beta-lactams, either as monotherapy (0.48) or in combination with rifampin (0.34

41 Patients received infusional avelumab monotherapy 10 mg/kg every 2 weeks until disease progres

42 rity in mean VA gain compared with anti-VEGF monotherapy (10.6 compared with 6.5 ETDRS letters at wee

43 n 147 (38%) of 384 patients with tofacitinib monotherapy, 173 (46%) of 376 patients with tofacitinib

44 s than 70 mg/dL, including 67.3% with statin monotherapy, 18.7% with statins plus ezetimibe, and 14%

45 py over 24 months from baseline (ranibizumab monotherapy -224.7 mum, ranibizumab with laser -248.9 mu

46 26 985 patients being treated with metformin monotherapy: 23.3%, 20.4%, 20.3%, and 20% across the HbA

47 es 4-8) to either 5 years of oral exemestane monotherapy (25 mg once a day) or a sequential scheme of

48 were treated with vitamin K antagonist (VKA) monotherapy, 25,458 (35%) with acetylsalicylic acid (ASA

49 3 (6%) of 384 patients receiving tofacitinib monotherapy, 26 (7%) of 376 patients receiving tofacitin

50 weeks for four doses, followed by nivolumab monotherapy 3 mg/kg every 2 weeks (N = 409).

51 3 weeks for four doses followed by nivolumab monotherapy 3 mg/kg every 2 weeks until progression or t

52 follow-up, 50405 were exposed to thiopurine monotherapy, 30294 to anti-TNF monotherapy, and 14229 to

53 ents received treatment (384 had tofacitinib monotherapy; 376 had tofacitinib and methotrexate; and 3

54 tween those receiving combination therapy or monotherapy (47 [35%] of 135 vs 85 [41%] of 208; adjuste

55 d (1:1 ratio) to receive either chlorambucil monotherapy (6 mg/m(2)/d orally on weeks 1 to 6, 9 to 10

56 iled to remit with venlafaxine hydrochloride monotherapy, 91 received aripiprazole and 90 received pl

57 ever, <40% of patients treated with thiazide monotherapy achieve BP control.

58 was higher among those exposed to thiopurine monotherapy (adjusted hazard ratio [aHR], 2.60; 95% CI,

59 e entire tumor, which brings the efficacy of monotherapies against a single target into question.

60 t CRF1 receptor antagonists lack efficacy as monotherapy agents for these conditions.

61 ation therapy vs those exposed to thiopurine monotherapy (aHR, 2.35; 95% CI, 1.31-4.22; P < .001) or

62 2.60; 95% CI, 1.96-3.44; P < .001), anti-TNF monotherapy (aHR, 2.41; 95% CI, 1.60-3.64; P < .001), or

63 35; 95% CI, 1.31-4.22; P < .001) or anti-TNF monotherapy (aHR, 2.53; 95% CI, 1.35-4.77; P < .001).

64 the suprachoroidal space (SCS) compared with monotherapy alone (13.4 mum vs 5.3 mum at 3 months; P =

65 combinations had similar ORR to azacitidine monotherapy, although patients with CMML benefitted from

66 tic medications vs placebos or antipsychotic monotherapy among adults with schizophrenia.

67 permeability was measured after exposure to monotherapies and combination therapies.

68 ne the efficacy of anti-PD-1 (or anti-PD-L1) monotherapies and prompt further studies aimed at identi

69 treatment intensification, 51.5% used statin monotherapy and 1.7% used statins plus ezetimibe.

70 (n=303; 152 patients assigned to ambrisentan monotherapy and 151 patients to tadalafil monotherapy).

71 dy period; 1019 (71.9%) received beta-lactam monotherapy and 399 (28.1%) received beta-lactam plus ma

72 erse events was 8.1% and 12.5% for nivolumab monotherapy and 40.0% and 54.9% for combination therapy.

73 25,458 (35%) with acetylsalicylic acid (ASA) monotherapy and 8,962 (13%) with dual-therapy (VKA + ASA

74 Ribavirin monotherapy and a minimization of immunosuppression repr

75 in disease-free survival between exemestane monotherapy and a sequential scheme of tamoxifen followe

76 l-cause mortality, with the exception of ARB monotherapy and ARB plus ACEI.

77 beta-Lactam monotherapy and beta-lactam plus macrolide combination t

78 atment options were combined: (1) bortezomib monotherapy and bortezomib plus dexamethasone, and (2) t

79 otein phosphatase 2 A (PP2A) inhibitor, as a monotherapy and chemosensitizing agent for sAML using an

80 stay between children receiving beta-lactam monotherapy and combination therapy (median, 55 vs 59 ho

81 led to superior BCVA outcomes versus laser (monotherapy and combined with ranibizumab from month 6;

82 m, ranibizumab with laser -248.9 mum, laser [monotherapy and combined with ranibizumab from month 6]

83 ed aspergillosis was observed with ibrutinib monotherapy and DA-TEDDi-R.

84 Rituximab monotherapy and fludarabine-rituximab in combination are

85 chanisms for the inadequacies of l-thyroxine monotherapy and highlights the possible role for persona

86 the first-line TB drug isoniazid, both as a monotherapy and in combination therapy with rifampicin.

87 I discuss recent data on venetoclax used as monotherapy and in combination with monoclonal antibodie

88 of drug-naivety, use of oral agents, insulin monotherapy and insulin combination therapy were 2.9%, 6

89 et treatment for 90 days followed by aspirin monotherapy and intensive management of vascular risk fa

90 omib plus dexamethasone, and (2) thalidomide monotherapy and thalidomide plus dexamethasone.

91 achieved an overall response with ofatumumab monotherapy and this treatment was well tolerated, with

92 n 11 (20%) patients receiving corticosteroid monotherapy and three (6%) patients on supportive care (

93 n combination therapies (avoiding artesunate monotherapies) and single gametocytocidal low dose of pr

94 nst cryptosporidiosis ie nitozoxanide, 25 in monotherapy, and 10 in association with azithromycin, 13

95 to thiopurine monotherapy, 30294 to anti-TNF monotherapy, and 14229 to combination therapy.

96 of 6-month isoniazid monotherapy, rifampicin monotherapy, and combination therapies with 3 to 4 month

97 patients with hypertension are treated with monotherapy, and control rates are poor because monother

98 Lithium monotherapy, sertraline monotherapy, and lithium/sertraline combination therapy

99 of patients who were receiving aripiprazole monotherapy, and to healthy subjects.

100 e categorized as being exposed to thiopurine monotherapy, anti-TNF monotherapy, or combination therap

101 Further options for monotherapy are needed to treat newly diagnosed epilepsy

102 herapy, the majority came from the letrozole monotherapy arm (n = 318), followed by sequential tamoxi

103 ly an intravitreal injection of aflibercept (monotherapy arm), followed by monthly intravitreal aflib

104 parum malaria treatment trials (n = 40) with monotherapy arms containing artemisinin or a derivative

105 PT (aspirin plus thienopyridine) and aspirin monotherapy at 30 days post-operatively.

106 Venetoclax monotherapy at a daily dose up to 1200 mg has an accepta

107 Eligible patients received WTX101 monotherapy at a starting dose of 15-60 mg/day on the ba

108 Despite the success of monotherapies based on blockade of programmed cell death

109 tes, we subjected Nos2 (-/-) mice with TB to monotherapy before or after establishment of human-like

110 umab (anti-programmed cell death receptor 1) monotherapy beyond Response Evaluation Criteria in Solid

111 patients treated with ledipasvir/sofosbuvir monotherapy, black patients had significantly lower SVR

112 benznidazole + posaconazole and benznidazole monotherapy (both 96%) versus placebo (17%) and posacona

113 general, CDK4/6 inhibitors are cytostatic as monotherapy but demonstrate favorable tolerability, whic

114 ate tumor growth in nude mice, compared with monotherapy, by reversing the expression of miR-34a, SIR

115 strategies including avoidance of antibiotic monotherapy, combination treatment with topical modaliti

116 a mouse xenograft model of human PDAC, PARPi monotherapy combined with targeted silencing of HuR sign

117 To assess the effect of bivalirudin monotherapy compared with unfractionated or low-molecula

118 acy, safety, and tolerability of semaglutide monotherapy, compared with placebo, in treatment-naive p

119 Patients who received D monotherapy could cross over to D + T 150/2 postprogress

120 Fluticasone/salmeterol and fluticasone monotherapy decreased peripheral airway smooth muscle re

121 Gant61 monotherapy did not alter the drug sensitivity of naive

122 N: The addition of vandetanib to gemcitabine monotherapy did not improve overall survival in advanced

123 rved, late disease stage-initiated anti-CD20 monotherapy did not inhibit T1D, and in this study was a

124 %) of the 384 patients receiving tofacitinib monotherapy died.

125 duction of combination therapy compared with monotherapy differed by eGFR (P=0.04).

126 raltegravir; or alone as protease inhibitor monotherapy (discontinued after week 96).

127 Patients on methylphenidate monotherapy displayed an increased rate of manic episode

128 imab talirine and determined the recommended monotherapy dose in patients with relapsed or refractory

129 At the recommended monotherapy dose of 40 microg/kg, the complete remission

130 The recommended monotherapy dose of vadastuximab talirine is 40 microg/k

131 tal cancers are insensitive to RAF inhibitor monotherapy due to feedback reactivation of receptor tyr

132 Fluticasone/salmeterol and fluticasone monotherapy equally reverse peripheral airway smooth mus

133 is study aimed at comparing EVL plus BB with monotherapy (EVL or BB) on all-source rebleeding and mor

134 proof-of-concept phase Ib study of ibrutinib monotherapy followed by ibrutinib plus chemotherapy (DA-

135 scular endothelial growth factor (VEGF) drug monotherapy for 1 year from the American Academy of Opht

136 Therefore, it might be useful as first-line monotherapy for adults with newly diagnosed epilepsy.

137 A cross-sectional study included patients in monotherapy for at least 36 months with Tafluprost 0.001

138 herapy conferred no benefit over beta-lactam monotherapy for children hospitalized with community-acq

139 volumab is well tolerated and effective as a monotherapy for patients with metastatic SCCA.

140 e and capecitabine compared with gemcitabine monotherapy for resected pancreatic cancer.

141 apy proved superiority compared with aspirin monotherapy for the prevention of ischemic events, despi

142 s been proposed as an alternative to insulin monotherapy for treating type 1 diabetes since deletion

143 clinical activity of intravenous ofatumumab monotherapy for untreated and relapsed Waldenstrom's mac

144 ml/min per 1.73 m(2): 6-month corticosteroid monotherapy; GFR=30-59 ml/min per 1.73 m(2): cyclophosph

145 and 8.6 months (95% CI, 7.6 to 10.4) in the monotherapy group (hazard ratio for death, 0.95; 95% CI,

146 %) of 280 patients in the protease inhibitor monotherapy group at week 96 (p<0.0001).

147 n the study in an elderly participant in the monotherapy group who died of cardiovascular failure 13

148 [11%] of 585 reported adverse events in the monotherapy group), diarrhoea (56 [10%] of 556 vs 64 [11

149 on therapy after week 96; protease inhibitor monotherapy group).

150 ion group, 288 patients) or lomustine alone (monotherapy group, 149 patients).

151 In the protease inhibitor monotherapy group, 292 (78%) of 375 had viral loads of l

152 ation group and 38.1% of the patients in the monotherapy group.

153 hree in the combination group and one in the monotherapy group.

154 on therapy group compared with the anti-VEGF monotherapy group.

155 rence 10.0, 95% CI 0.2-19.8, p=0.046) in the monotherapy group.

156 longer in the combination group than in the monotherapy group: 4.2 months versus 1.5 months (hazard

157 in the combination group vs 4.0 days in the monotherapy group; p=0.21).

158 icantly higher overall dropout rate than the monotherapy groups but did not have an accelerated time

159 uggested that patients receiving clopidogrel monotherapy had a lower risk of cardiovascular events th

160 CTLA-4 (ipilimumab) or anti-PD-1 (nivolumab) monotherapy has not been demonstrated to be of substanti

161 therapy, switching from statins to ezetimibe monotherapy, having International Classification of Dise

162 By the study end, both monotherapies improved renal function, decreasing glomer

163 e is evidence that n-3 PUFAs supplementation monotherapy improves clinical symptoms and cognitive per

164 n regimens can provide greater efficacy than monotherapies in malignant mesothelioma are ongoing.

165 emcitabine and capecitabine with gemcitabine monotherapy in 730 evaluable patients with resected panc

166 fficient condition for response to ADI-PEG20 monotherapy in AML.

167 led from 889 patients who received nivolumab monotherapy in clinical studies, including phase III tri

168 e more effective than inhaled corticosteroid monotherapy in controlling disease exacerbations, but th

169 h benznidazole were superior to benznidazole monotherapy in eliminating T. cruzi parasites measured b

170 razole-domperidone combination vs omeprazole monotherapy in gastroesophageal reflux disease (GERD).

171 ance the antitumor activity of ALK inhibitor monotherapy in human neuroblastoma cell lines and xenogr

172 ion therapy seemed to be more effective than monotherapy in individuals with moderately reduced eGFR

173 mpted investigation into its use as adjuvant monotherapy in participants with high-risk ccRCC.

174 is to assess the safety profile of nivolumab monotherapy in patients with advanced melanoma and descr

175 VKA monotherapy in patients with AF was associated with a lo

176 asel, Switzerland) compared with ranibizumab monotherapy in patients with neovascular age-related mac

177 of improved benefit compared with anti-PD-1 monotherapy in patients with NSCLC, supporting further a

178 identified for a phase III trial of IMGN853 monotherapy in patients with platinum-resistant disease.

179 findings suggest that selinexor is safe as a monotherapy in patients with relapsed or refractory AML

180 ty in this dose-escalation study of CUDC-907 monotherapy in patients with relapsed or refractory lymp

181 combination therapy compared to beta lactam monotherapy in patients with sepsis.

182 ) inhibitor that has promising activity as a monotherapy in refractory indolent lymphomas.

183 was associated with lower mortality than was monotherapy in the high-mortality-score stratum (30 [48%

184 trametinib (T) combination therapy versus D monotherapy in the randomized phase II BRF113220 study p

185 elective serotonin reuptake inhibitors or as monotherapy in the treatment of OCD, although their effi

186 , supporting the study of adjuvant endocrine monotherapy in this group.

187 wn enhanced antitumor activity compared with monotherapy in tumor types such as melanoma.

188 umour growth compared to L-ALD, when used as monotherapy in vivo.

189 We defined the referent as beta-lactam monotherapy, including exclusive use of an oral or paren

190 .73 m(2) Compared with individuals receiving monotherapy, individuals receiving combination therapy w

191 In conclusion, only corticosteroid monotherapy induced disease remission in a minority of p

192 olide combination therapy or fluoroquinolone monotherapy initiated within 4 to 8 hours of hospital ar

193 41-0.67), 32 in patients exposed to anti-TNF monotherapy (IR, 0.41; 95% CI, 0.27-0.55), and 14 in pat

194 -0.29), 70 in patients exposed to thiopurine monotherapy (IR, 0.54; 95% CI, 0.41-0.67), 32 in patient

195 However, ART monotherapy is associated with a high frequency of recru

196 Long-term entecavir monotherapy is highly effective at preventing HBV reacti

197 of ERK signaling, suggesting that sequential monotherapy is ineffective and selects for a progressive

198 t for background therapy suggested that ARNI monotherapy is more efficacious than ACEI or ARB monothe

199 Benznidazole monotherapy is superior to posaconazole, with high RT-PC

200 elet therapy reduces VTE risk beyond aspirin monotherapy is unknown.

201 chieve optimal glycemic control with insulin monotherapy, is the addition of oral hypoglycemic agents

202 VP or R-CVP (combination phase), followed by monotherapy maintenance in responders for a 2-year perio

203 apy or switching from combination therapy to monotherapy may be considered in very select low-risk pa

204 d pointed to circumstances where intravenous monotherapy may be inadequate.

205 pite their respective therapeutic benefit as monotherapy, may together provide antagonistic clinical

206 ab with laser was noninferior to ranibizumab monotherapy (mean average BCVA change: 15.4 vs. 15.0 let

207 esults Among patients who received nivolumab monotherapy, median progression-free survival was 3.0 mo

208 They also suggest that favipiravir monotherapy merits further study in patients with medium

209 letrozole-tamoxifen (n = 176), and tamoxifen monotherapy (n = 106).

210 ) demonstrated noninferiority of beta-lactam monotherapy (n = 506) vs beta-lactam plus macrolide comb

211 and received combination therapy (n=302) or monotherapy (n=303; 152 patients assigned to ambrisentan

212 ive combination antiviral therapy (n=316) or monotherapy (n=317).

213 ceive lithium monotherapy (N=49), sertraline monotherapy (N=45), or combination treatment with lithiu

214 on were randomly assigned to receive lithium monotherapy (N=49), sertraline monotherapy (N=45), or co

215 Compared with aspirin monotherapy, no associated differences were observed in

216 acy over time in many patients suggests that monotherapy of anti-VEGF protein therapeutics may benefi

217 otherapy, and control rates are poor because monotherapy only reduces blood pressure by around 9/5 mm

218 iate therapy, between those receiving active monotherapy (only one active drug) or combination therap

219 d tolerability of lacosamide as a first-line monotherapy option for these patients.

220 umours were treated with L-ALD or t-L-ALD as monotherapies or in combination with ex vivo-expanded Vg

221 rivaroxaban 15 mg daily plus P2Y12 inhibitor monotherapy or 2.5 mg rivaroxaban twice daily plus DAPT

222 d trial of daily oral PrEP (either tenofovir monotherapy or a combination of tenofovir and emtricitab

223 Among adults with IBD, the use of thiopurine monotherapy or anti-TNF monotherapy was associated with

224 irmed pneumonia and who received beta-lactam monotherapy or beta-lactam plus macrolide combination th

225 tients (31.7%) receiving either benznidazole monotherapy or combined with posaconazole.

226 mputer-generated code, to receive lacosamide monotherapy or controlled-release carbamazepine (carbama

227 studies assessed the role of metformin as a monotherapy or dual therapy supplement and found signifi

228 Oral administration of CFI-402257 in monotherapy or in combination with an anti-programmed ce

229 rting the use of anti-VEGF agents, either as monotherapy or in combination with laser therapy.

230 Posaconazole monotherapy or posaconazole combined with benznidazole a

231 egimen of rivaroxaban plus a P2Y12 inhibitor monotherapy or rivaroxaban plus DAPT could reduce bleedi

232 nia associated with methylphenidate, used in monotherapy or with a concomitant mood-stabilizing medic

233 potent antiviral activity against subtype B (monotherapy or with ATV +/- RTV) and subtype C, and was

234 exposed to thiopurine monotherapy, anti-TNF monotherapy, or combination therapy, or being unexposed.

235 hey received tezacaftor-ivacaftor, ivacaftor monotherapy, or placebo.

236 receive oral tofacitinib (5 mg twice daily) monotherapy, oral tofacitinib (5 mg twice daily) plus me

237 nibizumab with or without laser versus laser monotherapy over 24 months from baseline (ranibizumab mo

238 osaconazole and 86.7% receiving benznidazole monotherapy (p < 0.0001 vs. posaconazole/placebo).

239 antly greater with combination versus either monotherapy (P<0.001).

240 us raltegravir group), or protease inhibitor monotherapy (plus raltegravir induction for first 12 wee

241 INTERPRETATION: Nivolumab monotherapy provided meaningful clinical benefit, irresp

242 y, we demonstrated that high dose sertraline monotherapy provided no benefit for the prevention of Eb

243 adjuvant chemotherapy with fluoropyrimidine monotherapy reduces the risk of recurrence and death by

244 Short 8-week ledipasvir/sofosbuvir monotherapy regimens should perhaps be avoided in black

245 r for patients receiving DAPT versus aspirin monotherapy respectively, in subgroups with pre-CABG ACS

246 bel study evaluated brentuximab vedotin (BV) monotherapy (results previously reported), BV plus dacar

247 the efficacy and safety of 6-month isoniazid monotherapy, rifampicin monotherapy, and combination the

248 l rotation to either pazopanib or everolimus monotherapy (rotating arm) or initiated everolimus (cont

249 SLT monotherapy safely provides significant IOP reduction in

250 Lithium monotherapy, sertraline monotherapy, and lithium/sertral

251 e therapy as soon as they are diagnosed, and monotherapy should be considered for those in the low-mo

252 ages, and long-term treatment with ribavirin monotherapy still ongoing) but without achieving a susta

253 Previous 16-week monotherapy studies showed that dupilumab substantially

254 Limited proof-of-concept monotherapy studies to evaluate safety and antiviral act

255 ed INSTI, showed potent activity in a 10 day monotherapy study and has a high in-vitro resistance bar

256 Simulations indicate that monotherapies that exclusively target VEGFR2 phosphoryla

257 Within users of AEDs in monotherapy, the prevalence of SGA ranged from 7.3% for

258 rease in viral shedding at day 3 relative to monotherapy, this difference was not associated with imp

259 sess the comparative efficacy of tofacitinib monotherapy, tofacitinib plus methotrexate, and adalimum

260 atients were weaned to a low-dose tacrolimus monotherapy together with monthly belatacept application

261 Only corticosteroid monotherapy transiently reduced proteinuria at 12 months

262 Comparisons with lonafarnib monotherapy treatment reveal additional bone mineral den

263 After clinical deterioration using meropenem monotherapy, treatment success was achieved after commen

264 While the results of monotherapy treatments are compelling, there is increasi

265 (600 mg) combination therapy or oseltamivir monotherapy twice daily for 5 days, given orally, and pa

266 icipants were divided into 3 groups based on monotherapy type.

267 disease or better could continue ADI-PEG 20 monotherapy until disease progression or withdrawal.

268 continued to receive rilotumumab or placebo monotherapy until disease progression, intolerability, w

269 p were allowed to continue with evofosfamide monotherapy until documented disease progression.

270 placebo followed by nintedanib plus placebo monotherapy until progression.

271 0R4 (mouse-rhesus chimeric alphaCD40, n = 6) monotherapy using a consistent, comparable dosing regime

272 98.34% CI -6 to 11]) but not for tofacitinib monotherapy versus either adalimumab and methotrexate (-

273 To compare the effectiveness of beta-lactam monotherapy vs beta-lactam plus macrolide combination th

274 randomized (1:1) in ambulance to bivalirudin monotherapy vs unfractionated or low-molecular-weight he

275 Subsequent BV monotherapy was allowed.

276 he use of thiopurine monotherapy or anti-TNF monotherapy was associated with a small but statisticall

277 Maintenance treatment with bevacizumab monotherapy was continued until progressive disease with

278 and hypersensitivity of HNSCC cells to CHKi monotherapy was found.

279 Tofacitinib monotherapy was not shown to be non-inferior to either c

280 These data suggest that 32 doses of BTZ monotherapy was not well tolerated and resulted in only

281 hile PD-1 blockade or IL10 neutralization as monotherapies were inefficient, combination of these two

282 ted association with long-acting pasireotide monotherapy were diarrhoea (15 [37%] of 41), hyperglycae

283 ted association with long-acting pasireotide monotherapy were gamma-glutamyltransferase increased (fo

284 clusion Treatment-related AEs with nivolumab monotherapy were primarily low grade, and most resolved

285 given transient late disease stage BAFFR-Fc monotherapy were rendered T1D resistant.

286 with a suspected association with everolimus monotherapy were stomatitis (26 [62%] of 42) and diarrho

287 ron alfa-2a once per week for 15 weeks, then monotherapy with 180 mug pegylated interferon alfa-2a on

288 likelihood of exposing patients to de facto monotherapy with a critical drug class (fluoroquinolones

289 aged 12 years or older, routinely prescribe monotherapy with an intranasal corticosteroid rather tha

290 n linked to recrudescence of parasites after monotherapy with ART and, possibly contributes to ART re

291 Monotherapy with autologous VSTs specific for cytomegalo

292 d MEAN enhanced tumor growth inhibition over monotherapy with either agent.

293 teractive web response system to 26 weeks of monotherapy with fixed-dose oral cariprazine (3 mg, 4.5

294 ns for toxicity or tolerance; alternatively, monotherapy with gemcitabine or fluorouracil plus folini

295 Conclusion Monotherapy with labetuzumab govitecan demonstrated a ma

296 amantadine, and ribavirin versus oseltamivir monotherapy with matching placebo for the treatment of i

297 tric rehospitalization was the lowest during monotherapy with once-monthly long-acting injectable pal

298 olar disorder is indicated before initiating monotherapy with psychostimulants.

299 tomatic peripheral artery disease to receive monotherapy with ticagrelor (90 mg twice daily) or clopi

300 transplant recipients treated with entecavir monotherapy without hepatitis B immune globulin.